FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Relevant for: People with triple negative breast cancer, In portal: Breast Cancer
Guideline : FDA asks Allergan to recall certain textured breast implants
Most relevant for: Women with, or considering breast reconstruction with implants
On July 25, 2019, the Food and Drug Administration requested that breast implant manufacturer Allergan recall its BIOCELL textured implants and expanders due to an association with a rare type of lymphoma called Breast Implant Associated Anaplastic Large Cell Lymphoma or BIA-ALCL. The FDA does not recommend removing implants for people who do not have disease symptoms. This XRAYS review updates information about this FDA recall. (7/29/19)
Read More
Guideline : FDA approves an immunotherapy treatment for some patients with triple-negative breast cancer
Most relevant for: People with metastatic, triple-negative breast cancer
THIS INFORMATION HAS BEEN UPDATED: In August 2021 Roche voluntarily withdrew their FDA accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1.
The FDA approved the use of the immunotherapy drug atezolizumab (Tecentriq) in combination with the chemotherapy agent nab-paclitaxel (Abraxane) for certain patients with advanced triple-negative breast cancer. (5/26/19)
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Smart drug shows promising results for treatment of metastatic triple-negative breast cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with metastatic, triple-negative breast cancer
THIS INFORMATION HAS BEEN UPDATED on 04/27/20: Based on the results from the study reviewed in this XRAY, the U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hizy (Trodelvy), as a treatment for people with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.
We report results of an early-stage clinical trial of a new class of drugs for metastatic triple-negative breast cancer (TNBC). IMMU-132 is a combination of two different molecules: an antibody that targets certain types of cancer and delivers a chemotherapy drug that can kill cancer cells. This study looks at whether IMMU-132 is safe and effective for treating metastatic TNBC. (4/16/19)
Read More
Relevance: Medium-High
Research Timeline: Post Approval
Guideline : Breast surgeons recommend genetic testing for all breast cancer patients
Relevance: Medium-High
Research Timeline: Post Approval
Most relevant for: Anyone diagnosed with breast cancer
The American Society of Breast Surgeons published statement on genetic testing for hereditary breast cancer on February 10, 2019. It includes recommendations about who should be tested. Among these is the recommendation that all breast cancer patients get genetic testing, as well as women who do not have breast cancer but fit the National Comprehensive Cancer Network (NCCN) guidelines. (3/25/19)
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Prevalence of BRCA founder mutations in Bahamian women
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Bahamanian women
The Bahamas has the highest known frequency of BRCA mutations among people diagnosed with breast cancer. This study reviewed whether population-based BRCA testing (testing everyone regardless of family or personal history of cancer) would be an effective approach for finding mutation carriers in the Bahamas. (3/4/19)
Read More
Relevance: Medium-Low
Strength of Science: Low
Research Timeline: Post Approval
Study : Breast cancer implant study suggests links with illness but has serious flaws
Relevance: Medium-Low
Strength of Science: Low
Research Timeline: Post Approval
Most relevant for: Women with or considering breast implant reconstruction
THIS INFORMATION HAS BEEN UPDATED: In October 2021, the FDA issued guidance for people with breast implants Read our latest review on this topic.
An article in the Annals of Surgery, researchers conclude that their work supports an association between silicone breast implants and a range of conditions. This journal article was accompanied by two editorials in which experts voiced their disagreement with the way the analysis was performed and the conclusions of the authors. (2/21/19)
Read More
Article : The cost of cancer care and impact of financial hardship on treatment
Most relevant for: Anyone diagnosed with cancer
Several recent studies on the cost of cancer care show the negative effects on cancer patients. We review an article by Kaiser Health News and associated studies about the financial impact of breast cancer treatment and cost of precision medicine. (2/8/19)
Read More
Relevance: Medium-High
Study : FORCE online survey: What breast cancer information do young women want and where do they look for it?
Relevance: Medium-High
Most relevant for: Young women and the health care providers who treat them
FORCE developed the CDC-funded Examining Relevance of Articles to Young Survivors or XRAYS program to help young breast cancer survivors and those at high-risk better understand media coverage about new breast cancer research. To ensure that the program would be responsive to users’ needs, FORCE designed a web-based survey to assess where young women look for information about breast cancer and to learn their unmet information needs. The results of this survey were published in the journal Health Communications. (1/18/19)
Read More.jpeg)
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Improving outcomes for young women with breast cancer: fertility and childbearing issues
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: Women diagnosed with breast cancer at a young age
Fertility issues and family planning decisions are prominent concerns for young women with breast cancer. This XRAYS looks at Dr. Ann Partridge’s presentation at the 2018 San Antonio Breast Cancer symposium. Her talk, “Breast cancer in young women: Understanding differences to improve outcomes," focused on initial findings from the Young Women's Breast Cancer Study. Dr. Partridge’s research continues in the currently enrolling POSITIVE trial which tests whether women can safely interrupt adjuvant endocrine therapy in order to get pregnant. (1/7/19)
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Inherited breast cancer in Nigerian women
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: Nigerian women or women of Nigerian descent who have breast cancer
A new study shows that among Nigerian women, one in eight cases of breast cancer is due to an inherited mutation in BRCA1, BRCA2, PALB2 or TP53. (12/5/18)
Read More